Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorMuro, Kei
dc.contributor.authorSalinardi, Taylor
dc.contributor.authorSingh, Arvind Rup
dc.contributor.authorMacarulla Mercadé, Teresa
dc.date.accessioned2021-09-20T13:06:24Z
dc.date.available2021-09-20T13:06:24Z
dc.date.issued2020-03-31
dc.identifier.citationMuro K, Salinardi T, Singh AR, Macarulla T. Safety of Aflibercept in Metastatic Colorectal Cancer: A Literature Review and Expert Perspective on Clinical and Real-World Data. Cancers. 2020 Mar 31;12:844.
dc.identifier.issn2072-6694
dc.identifier.urihttp://hdl.handle.net/11351/6333
dc.descriptionAflibercept; Anti-angiogenic therapy; Colorectal cancer
dc.description.abstractBackground: Metastatic colorectal cancer (mCRC) represents a substantial health burden globally and an increasing challenge in Asian countries. Treatment options include chemotherapy plus a vascular endothelial growth factor (VEGF) inhibitor (such as bevacizumab, aflibercept or ramucirumab), or anti-epidermal growth factor receptor (EGFR) therapies. Aflibercept, a recombinant fusion protein, has been approved for treatment of mCRC in combination with FOLFIRI for patients whose disease progresses during or after treatment with an oxaliplatin-containing regimen, based on its efficacy and tolerability profile in clinical trials. This report aims to provide an overview of both clinical and real-world evidence and experience on the use of aflibercept in routine clinical practice, with a focus on European, American and Asian populations. Methods: A literature search was conducted in PubMed (on 28th February 2019) using the search terms ("aflibercept") and ("Colorectal"OR"CRC") to identify publications containing information on aflibercept-containing regimens. Results: The adverse events (AE) profile was similar between geographical locations. Across trials, real-world and retrospective studies, grade ≥ 3 hypertension and proteinuria were amongst the most frequently reported AEs. Conclusions: The safety profile of aflibercept is generally manageable and comparable across various geographic locations.
dc.language.isoeng
dc.publisherMDPI
dc.relation.ispartofseriesCancers;12
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectProteïnes recombinants
dc.subjectCòlon - Càncer - Tractament
dc.subjectRecte - Càncer - Tractament
dc.subject.meshColorectal Neoplasms
dc.subject.mesh/drug therapy
dc.subject.meshRecombinant Fusion Proteins
dc.titleSafety of Aflibercept in Metastatic Colorectal Cancer: A Literature Review and Expert Perspective on Clinical and Real-World Data
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.3390/cancers12040844
dc.subject.decsneoplasias colorrectales
dc.subject.decs/farmacoterapia
dc.subject.decsproteínas de fusión recombinantes
dc.relation.publishversionhttps://doi.org/10.3390/cancers12040844
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Muro K] Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya 464-8681, Japan. [Salinardi T, Singh AR] Global Medical Oncology, Sanofi, Boston, MA 02142, USA. [Macarulla T] Grup de Tumors gastrointestinals, Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. IOB, Barcelona, Spain
dc.identifier.pmid32244546
dc.identifier.pmid000535587400073
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record